A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.

Background: In approximately 15% of human cancers, telomere length is maintained independently of telomerase by the homologous recombination (HR)-mediated alternative lengthening of telomeres (ALT) pathway. Whether the ALT pathway can be exploited for therapeutic treatment remains unknown. The purpo...

Descripción completa

Detalles Bibliográficos

Publicado en:	JNCI: Journal of the National Cancer Institute Vol. 109; no. 10; pp. 1 - 12
Autores principales:	Xiao-hui Zheng, Xin Nie, Yiming Fang, Zepeng Zhang, Yingnan Xiao, Zongwan Mao, Haiying Liu, Jian Ren, Feng Wang, Lixin Xia, Junjiu Huang, Yong Zhao, Zheng, Xiao-Hui, Nie, Xin, Fang, Yiming, Zhang, Zepeng, Xiao, Yingnan, Mao, Zongwan, Liu, Haiying, Ren, Jian
Formato:	pictorial research tables/charts Journal Article
Publicado:	Oxford University Press / USA Oct2017
Acceso en línea:	Ver este registro en EBSCOhost